AGE prevention to combat first signs of aging

DermalRx® LuShield™ NAT



DermalRx® LuShield™ NAT is a nature-inspired active designed to help combat the molecular drivers behind the first signs of skin aging. Based on a proprietary extract of *Osmanthus fragrans*, this sustainably-sourced botanical helps prevent the production of Advanced Glycation End Products (AGEs); damaging compounds that accumulate over time and contribute to loss of elasticity, inflammation, oxidative stress and declining skin resilience, resulting in the appearance of skin wrinkles, sagging, dullness and uneven tone.


DermalRx LuShield NAT inhibits 95% of AGE formation.

DermalRx LuShield NAT works on multiple fronts to help re-establish and support youthful-looking skin. In addition to AGEs formation prevention, it provides strong antioxidant activity, inhibits pollution-induced inflammatory signaling and supports the expression of skin-relevant genes involved in extracellular matrix health. By helping protect the skin's structural foundation, DermalRx LuShield NAT supports the function of collagen, elastin and fibroblasts associated with firmness and elasticity.

In a 4-week clinical study using 3% DermalRx LuShield NAT, 100% of panelists showed improvement in skin firmness and elasticity; delivered forehead and under-eye line mitigation; and promoted improvement with skin redness, clarity, brightness and overall tone.

Applications

- **Anti-aging and Longevity**: regimes targeting oxidative and glycation-induced damage (caused by pollution, UV radiation, etc.)
- **Protection and Pollution Defense**: regimes targeting oxidative and glycation-induced damage
- **Skin Soothing and Calming**: Refine texture, improve hydration, and reduce redness



DermalRx® LuShield™ NAT
Product ID – R10139
Suggested Use Level – 1%-3%
Propanediol (and) Osmanthus Fragrans Flower Extract

DermalRx® LuShield™ NAT | epigenetic profile

RAGE activation is the primary sensor of AGEs. It triggers downstream NF-κB and ROS production, altering ECM gene expression.

UPREG

MMP9 (an enzyme important for strong ROS-response gelatinase)
TIMP3 (which decreases under glycation stress)
COL1A1 COL4A2 COL5A1 COL7A1 (their protein products are AGE targets)
ECM1 (RAGE-induced remodeling causes shifts in ECM organization)

DOWNREG

MMP1 (most responsible to AGE-RAGE signaling)
MMP3 (increases with NF-κB activation)

DermalRx® LuShield™ NAT enhances the production of essential proteins that combat the effects of AGEs

©2026 Biocogent, LLC Rev 1
™/® - Trademark of Biocogent, LLC.
® - Registered in the U.S. Patent and Trademark Office and in other countries.
except VISIA® a registered trademark of Canfield Scientific, Inc.

15 Pinehurst Drive
Bellport, NY 11713 USA

Biocogent

Tel: +1 631.866.1800 | Fax: +1 631.638.1303
info@biocogent.com | biocogent.com


Clinical Highlight Report

DermalRx® LuShield™ NAT

Proven Performance | Visible Results | Elevated Beauty

Clinically tested and consumer validated, DermalRx® LuShield™ NAT is a nature-inspired AGE-prevention active that helps protect skin from glycation-driven aging while improving firmness, elasticity and the appearance of fine lines.


60 healthy male and female panelists | baseline, 2 and 4 weeks evaluation | Expert Grading, VISIA®
Treated group used face cream with 3% DermalRx LuShield NAT | Placebo group used blank, otherwise identical face cream | All panelists applied cream twice daily, AM and PM



increase 16%+ by week 4

Elasticity


100% panelist improvement by 4 weeks
+16.62% mean change at 4 weeks*
Progressive improvement



increase 16%+ by week 4

Firmness


100% panelist improvement by 4 weeks
+16.48% mean change at 4 weeks*
Progressive improvement



reduction 13%+ by week 4

Forehead Lines

86.67% panelist improvement by 4 weeks
+13.04% mean change at 4 weeks*
Notable reduction of fine lines



reduction 12%+ by week 4

Under Eye Lines

90% panelist improvement by 4 weeks
+12.54% mean change at 4 weeks*
Visible improvement of under eye lines



Formulate for longevity with proven AGE prevention.

biocogent.com/NAT

For full clinical findings, formulary and other features, visit biocogent.com/NAT

* Statistically significant improvement compared to the placebo group